In the present study. we analysed human choriocarcinoma cell lines for abnormalities in the tumour-suppressor gene p53 by Southern blotting, Northern blotting, non-radioisotopic single-stranded conformational polymorphism (SSCP) and complementary DNA sequencing. In all cell lines (Bewo, GCH-1, GCH-2. SCH, JAR, JEG-3. NUC-1 and HCCM-5), no p53 gene abnormality was detected by using Southern blotting. p53 mRNA of the expected size was detected in all cell lines tested by Northern blotting. SSCP analysis revealed abnormalities of p53 cDNA in the SCH cell line. Sequencing analysis of the entire coding region of the p53 gene revealed that both alleles were expressed in the JEG-3 cell line, and one of the alleles contained a point mutation (G to T) in codon 167 (Gln to His). In the NUC-1 cell line both alleles were point mutated. One allele had a point mutation (A to T) that resulted in a codon 17 change (Glu to Asp), and another had a point mutation (A to T) that caused a codon 24 change (Lys to Asn). In the SCH cell line, AGG was inserted between codon 249 and 250; this insertion resulted in an abnormal structure of the p53 protein. In three out of eight human choriocarcinoma cell lines, a p53 gene abnormality was detected. Therefore our data demonstrate that p53 gene abnormalities are associated with choriocarcinoma cell lines.
Choriocarcinoma is very malignant, and is frequently metastatic. The 30 year incidence of gestational choriocarcinoma is 2.46 cases per 100 000 pregnancies. There is an increased risk among women older than 45 years. Non-whites have an approximately 2-fold increased risk of gestational choriocarcinoma compared with whites (Buckley et al., 1984) . In Japan at present it is very difficult to obtain specimens of choriocarcinoma for study. Therefore we investigated human choriocarcinoma cell lines.
Genetic analysis of human tumours strongly suggests that a number of gene defects accumulate over time and interact to bring about derangement of growth control that ultimately results in malignancy (Bishop et al., 1991; Hollingsworth and Lee, 1991) . Increasing evidence supports the hypothesis that the p53 gene acts as a tumour-suppressor gene (Baker et al.. 1990 ; Strech et al., 1991) , and mutations of the p53 gene are frequently found in a variety of cancers (Rodriguez et al.. 1990; Davidoff et al., 1991) . Recently, oncogene activation and tumour-suppressor gene inactivation have been reported in some human gynaecological tumours Westphal, 1991, 1992; Yaginuma et al., 1993) , but in choriocarcinoma this has not been analysed previously. Therefore, in the present study, we used molecular biology techniques to analyse p53 gene abnormalities in human choriocarcinoma cell lines. al., 1985) . The 1.9 kb fragment of php53c-1, including the entire p53-coding region, was used as a probe. This fragment was labelled with [a-32PJdCTP using the Random Primer Kit (Stratagene).
Materials and methods

Cell lines
RNA isolation and Northern blot analysis Total RNA was extracted from cells by the guanidinium thiocyanate extraction procedure (Ausubel et al., 1989) . Total placental RNA was used as a control. Samples (20 Lg) were denatured with 6.3% formaldehyde and 50% formamide, subjected to electrophoresis on a 1% agarose gel, transferred to a nylon membrane and hybridised with the labelled p53 probe.
Non-radioisotopic poltmerase chain reaction (PCR)-SSCP and sequencing of the entire coding region of the p53 cDNA Non-radioisotopic PCR-SSCP was accomplished according to an adapted version of a previously reported method (Reiss et al., 1992; Imamura et al., 1993; Marchetti et al., 1993) . Electrophoresis was carried out in a non-denaturing 10-20% gradient gel (polyacrylamide gel) at 4'C, and PCR products were separated with 100 V constant voltage, following silver staining to visualise the bands.
Complementary DNA was generated from total RNA using 200 units of the Molony strain of murine leukaemia virus reverse transcriptase (BRL) with oligo(dT) as a primer. A 1.3 kb fragment including the entire p53-coding region was generated from the complementary DNA by PCR. Sequencing of the entire p53-coding region was performed as reported previously (Yaginuma and Westphal, 1991 Table I 
